MCID: CNT018
MIFTS: 34

Central Nervous System Leukemia

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Central Nervous System Leukemia

MalaCards integrated aliases for Central Nervous System Leukemia:

Name: Central Nervous System Leukemia 12 15 71
Leukemia of the Cns 12

Classifications:



External Ids:

Disease Ontology 12 DOID:12969
NCIt 49 C5440
UMLS 71 C1332884

Summaries for Central Nervous System Leukemia

Disease Ontology : 12 A hematologic cancer located in the central nervous system.

MalaCards based summary : Central Nervous System Leukemia, also known as leukemia of the cns, is related to childhood acute lymphocytic leukemia and acute leukemia. An important gene associated with Central Nervous System Leukemia is CD19 (CD19 Molecule), and among its related pathways/superpathways are Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell and Hematopoietic Stem Cells and Lineage-specific Markers. The drugs Vincristine and Methotrexate have been mentioned in the context of this disorder. Affiliated tissues include central nervous system, myeloid and t cells, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Central Nervous System Leukemia

Diseases related to Central Nervous System Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 107)
# Related Disease Score Top Affiliating Genes
1 childhood acute lymphocytic leukemia 29.9 MME AFF1
2 acute leukemia 29.5 CD7 CD34 CD33 ANPEP AFF1
3 precursor t-cell acute lymphoblastic leukemia 29.4 CD7 CD34 CD33 ANPEP
4 leukemia, acute lymphoblastic 3 29.2 MME CD34 CD19 ANPEP AFF1
5 lymphoma, non-hodgkin, familial 28.9 MME CD7 CD34 CD19 CARTPT
6 acute promyelocytic leukemia 28.8 CD7 CD34 CD33 ANPEP
7 hematologic cancer 28.8 MME CD7 CD34 CD33 CD19
8 pancytopenia 28.7 CD7 CD34 CD33 CD19 ANPEP
9 leukemia, acute lymphoblastic 28.4 MME CD7 CD34 CD33 CD19 CARTPT
10 leukemia, acute myeloid 27.8 MME CD7 CD34 CD33 CD19 CARTPT
11 leukemia 10.7
12 adult lymphoma 10.3 MME CD19
13 spleen cancer 10.3 MME CD19
14 cll/sll 10.3 MME CD19
15 mulchandani-bhoj-conlin syndrome 10.3 MME CD19
16 plasma protein metabolism disease 10.3 MME CD19
17 b-cell adult acute lymphocytic leukemia 10.2 CD19 ANPEP
18 cardiomyopathy, dilated, 1c, with or without left ventricular noncompaction 10.2 CD33 CD19
19 refractory hematologic cancer 10.2 CD19 CARTPT
20 relapsed/refractory diffuse large b-cell lymphoma 10.2 CD19 CARTPT
21 splenic disease 10.2 MME CD19
22 leukemia, chronic myeloid 10.2
23 aleukemic leukemia cutis 10.2 CD33 ANPEP
24 capillary leak syndrome 10.1 CD19 CARTPT
25 childhood leukemia 10.1
26 myeloid leukemia 10.1
27 breast myofibroblastoma 10.1 MME CD34
28 breast leiomyoma 10.1 MME CD34
29 mucocele of appendix 10.1 MME CD34
30 pacinian tumor 10.1 MME CD34
31 inflammatory liposarcoma 10.1 MME CD34
32 intravenous leiomyomatosis 10.1 MME CD34
33 sarcomatoid squamous cell skin carcinoma 10.1 MME CD34
34 cervical polyp 10.1 MME CD34
35 pulmonary artery leiomyosarcoma 10.1 MME CD34
36 vulvar leiomyoma 10.1 MME CD34
37 hemorrhagic cystitis 10.1 CD34 CD19
38 sclerosing hepatic carcinoma 10.1 MME CD34
39 breast malignant phyllodes tumor 10.1 MME CD34
40 spherocytosis, type 5 10.1 CD34 CD19
41 central nervous system hematologic cancer 10.1 MME CARTPT
42 endobronchial leiomyoma 10.1 MME CD34
43 mucinous tubular and spindle renal cell carcinoma 10.1 MME CD34
44 breast sarcoma 10.1 MME CD34
45 vaginal endometrial stromal sarcoma 10.1 MME CD34
46 central epithelioid sarcoma 10.1 MME CD34
47 vulvar proximal-type epithelioid sarcoma 10.1 MME CD34
48 vagina sarcoma 10.1 MME CD34
49 sweat gland benign neoplasm 10.1 MME CD34
50 plasma cell neoplasm 10.0 MME CD19

Graphical network of the top 20 diseases related to Central Nervous System Leukemia:



Diseases related to Central Nervous System Leukemia

Symptoms & Phenotypes for Central Nervous System Leukemia

GenomeRNAi Phenotypes related to Central Nervous System Leukemia according to GeneCards Suite gene sharing:

26 (show all 22)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.68 WFIKKN2
2 Increased shRNA abundance (Z-score > 2) GR00366-A-131 9.68 WFIKKN2
3 Increased shRNA abundance (Z-score > 2) GR00366-A-135 9.68 AFF1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-136 9.68 WFIKKN2
5 Increased shRNA abundance (Z-score > 2) GR00366-A-139 9.68 CD34
6 Increased shRNA abundance (Z-score > 2) GR00366-A-150 9.68 WFIKKN2
7 Increased shRNA abundance (Z-score > 2) GR00366-A-159 9.68 AFF1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.68 WFIKKN2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-170 9.68 WFIKKN2
10 Increased shRNA abundance (Z-score > 2) GR00366-A-197 9.68 WFIKKN2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-203 9.68 AFF1 CD34
12 Increased shRNA abundance (Z-score > 2) GR00366-A-24 9.68 CD34
13 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.68 WFIKKN2
14 Increased shRNA abundance (Z-score > 2) GR00366-A-36 9.68 AFF1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.68 CD34
16 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.68 AFF1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-58 9.68 AFF1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-59 9.68 AFF1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-60 9.68 AFF1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-77 9.68 WFIKKN2
21 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.68 AFF1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-84 9.68 WFIKKN2

Drugs & Therapeutics for Central Nervous System Leukemia

Drugs for Central Nervous System Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 47)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vincristine Approved, Investigational Phase 2, Phase 3 57-22-7, 2068-78-2 5978
2
Methotrexate Approved Phase 2, Phase 3 59-05-2, 1959-05-2 126941
3
Mercaptopurine Approved Phase 2, Phase 3 50-44-2 667490
4
Pegaspargase Approved, Investigational Phase 2, Phase 3 130167-69-0
5
leucovorin Approved Phase 2, Phase 3 58-05-9 6006 143
6
Prednisone Approved, Vet_approved Phase 2, Phase 3 53-03-2 5865
7
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2, Phase 3 1177-87-3
8
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
9
Dexamethasone Approved, Investigational, Vet_approved Phase 2, Phase 3 50-02-2 5743
10
Idarubicin Approved Phase 2, Phase 3 58957-92-9 42890
11
Etoposide Approved Phase 2, Phase 3 33419-42-0 36462
12
Cytarabine Approved, Experimental, Investigational Phase 2, Phase 3 147-94-4, 65-46-3 6253
13
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
14
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
15 Etoposide phosphate Phase 2, Phase 3
16 Hormones Phase 2, Phase 3
17 Anti-Infective Agents Phase 2, Phase 3
18 Antineoplastic Agents, Hormonal Phase 2, Phase 3
19 Vitamin B Complex Phase 2, Phase 3
20 Folic Acid Antagonists Phase 2, Phase 3
21 Hormone Antagonists Phase 2, Phase 3
22 Histone Deacetylase Inhibitors Phase 2, Phase 3
23 Antiviral Agents Phase 2, Phase 3
24 Alkylating Agents Phase 2, Phase 3
25 Immunosuppressive Agents Phase 2, Phase 3
26 Antiemetics Phase 2, Phase 3
27 Dermatologic Agents Phase 2, Phase 3
28 Folate Phase 2, Phase 3
29 Gastrointestinal Agents Phase 2, Phase 3
30 Immunologic Factors Phase 2, Phase 3
31 Tubulin Modulators Phase 2, Phase 3
32 glucocorticoids Phase 2, Phase 3
33 Antirheumatic Agents Phase 2, Phase 3
34 Vitamin B9 Phase 2, Phase 3
35 Antimetabolites Phase 2, Phase 3
36 Anti-Inflammatory Agents Phase 2, Phase 3
37
Liposomal doxorubicin Phase 3 31703
38 razoxane Phase 3
39 Cardiotonic Agents Phase 3
40
asparaginase Phase 3
41 Antibiotics, Antitubercular Phase 3
42 Antimitotic Agents Phase 3
43 Anti-Bacterial Agents Phase 3
44 Protective Agents Phase 3
45 Protein Kinase Inhibitors Phase 2
46 Imatinib Mesylate Phase 2 220127-57-1 123596
47 Cola

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 An Open-Label, One-Arm, Multi-Site Trial of Precision Diagnosis Directing Histone Deacetylase Inhibitor Chidamide Total Therapy for Adult T-lymphoblastic Lymphoma/Leukemia Recruiting NCT03564704 Phase 2, Phase 3 Dexamethasone;vincristine;Cyclophosphamide;Idarubicin;Pegaspargase;Adriamycin;Methotrexate;6-mercaptopurine.;Etoposide;Cytarabine;Chidamide
2 An Open-Label, One-Arm, Multi-Site Trial of Precision Diagnosis Directing Histone Deacetylase Inhibitor Chidamide Target Total Therapy for Adult Early T-cell Progenitor Acute Lymphoblastic Leukemia/Lymphoma Recruiting NCT03553238 Phase 2, Phase 3 Chidamide;Dexamethasone;vincristine;Cyclophosphamide;Idarubicin;Pegaspargase;Adriamycin;Methotrexate;6-Mercaptopurine;Etoposide;Cytarabine
3 Treatment of Childhood Acute Lymphoblastic Leukemia Terminated NCT00165087 Phase 3 asparaginase (E. Coli);asparaginase (Erwina);dexrazoxane;doxorubicin
4 Evaluation of Imatinib (GLIVEC) After Induction Therapy in Patients Aged More Than 55 Years With Philadelphia Positive Acute Lymphoblastic Leukaemia (Ph+ ALL) : a Non Randomised, Controlled, Open, Multicentric, International Phase II Clinical Study (CSTI 571 AFR09 Trial) Unknown status NCT00149136 Phase 2 imatinib
5 Descriptive Study to Evaluate the Information and Psychosocial Issues on the Risk on Infertility in Cancer Patients After Receiving Treatment in a Comprehensive Cancer Center Unknown status NCT01295463
6 Chemotherapy-induced Nausea and Vomiting in Children Receiving Intrathecal Methotrexate With/Without Vincristine Completed NCT01661413

Search NIH Clinical Center for Central Nervous System Leukemia

Genetic Tests for Central Nervous System Leukemia

Anatomical Context for Central Nervous System Leukemia

The Foundational Model of Anatomy Ontology organs/tissues related to Central Nervous System Leukemia:

19
Central Nervous System

MalaCards organs/tissues related to Central Nervous System Leukemia:

40
Myeloid, T Cells, Bone, Bone Marrow, Monocytes, B Cells, Brain

Publications for Central Nervous System Leukemia

Articles related to Central Nervous System Leukemia:

(show top 50) (show all 256)
# Title Authors PMID Year
1
The diagnostic and prognostic value of MRI in central nervous system involvement of acute myeloid leukemia: a retrospective cohort of 84 patients. 61
32567523 2020
2
Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features. 61
32453841 2020
3
Comparison of hemorrhagic and ischemic stroke after allogeneic hematopoietic stem cell transplantation. 61
32332920 2020
4
[Clinical Analysis of Dasatinib and Chemotherapy Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Treatment of Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia]. 61
32027247 2020
5
Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. 61
31944221 2020
6
Ponatinib therapy in recurrent Philadelphia chromosome-positive central nervous system leukemia with T315I mutation after Allo-HSCT. 61
31785158 2019
7
Disrupting the leukemia niche in the central nervous system attenuates leukemia chemoresistance. 61
31624109 2019
8
Glucocorticoids and selumetinib are highly synergistic in RAS pathway-mutated childhood acute lymphoblastic leukemia through upregulation of BIM. 61
30655370 2019
9
Anti-CD19 CAR-T as a feasible and safe treatment against central nervous system leukemia after intrathecal chemotherapy in adults with relapsed or refractory B-ALL. 61
30846865 2019
10
[The efficacy analysis of allogeneic hematopoietic stem cell transplantation in 48 leukemia patients with central nervous system leukemia]. 61
32397021 2019
11
Eradication of Central Nervous System Leukemia of T-Cell Origin with a Brain-Permeable LSD1 Inhibitor. 61
30518632 2019
12
[Detection Rate of Central Nervous System Leukemia Can Be Improved by Cell Preservation Solution]. 61
30738441 2019
13
Functional Improvement of Chimeric Antigen Receptor Through Intrinsic Interleukin-15Rα Signaling. 61
30444200 2019
14
Altered CSF Proteomic Profiling of Paediatric Acute Lymphocytic Leukemia Patients with CNS Infiltration. 61
31186631 2019
15
[Clinical Significance of Additional Chromosomal 8 Clonal Evolution in CML Progression]. 61
30501690 2018
16
Rhabdomyolysis during myelosuppression in a patient with central nervous system leukemia: A case report. 61
30407314 2018
17
Chronic myeloid leukemia extramedullary blast crisis presenting as central nervous system leukemia: A case report. 61
30407337 2018
18
Identifying and Understanding the Gaps in Care Experienced by Adolescent and Young Adult Cancer Patients at the University of Iowa Hospitals and Clinics. 61
29924681 2018
19
Radiation in Central Nervous System Leukemia: Guidelines From the International Lymphoma Radiation Oncology Group. 61
30102203 2018
20
[Treatment of central nervous system leukemia with CD19-chimeric antigen receptor T-cell immunotherapy: two cases report and literature review]. 61
30180466 2018
21
[Analysis of Prognostic Factors for 96 Patients with Acute Lymphoblastic Leukemia]. 61
30111398 2018
22
[Analysis of Factors Influencing Prognosis of 87 Adults with Ph Chromosome Negative ALL]. 61
30111399 2018
23
Haploidentical hematopoietic SCT using helical tomotherapy for total-body irradiation and targeted dose boost in patients with high-risk/refractory acute lymphoblastic leukemia. 61
29330392 2018
24
A retrospective comparison of Escherichia coli and polyethylene glycol-conjugated asparaginase for the treatment of adolescents and adults with newly diagnosed acute lymphoblastic leukemia. 61
29387211 2018
25
Experiment research of focused ultrasound combined with drug and microbubble for treatment of central nervous system leukemia. 61
29435190 2018
26
Central nervous system leukemia in a patient with concurrent nasopharyngeal carcinoma and acute myeloid leukaemia: A case report. 61
29384905 2017
27
[Clinical Analysis of 7 Children with Mature B-cell Acute Lymphoblastic Leukemia]. 61
29070107 2017
28
Outcome and Clinical Significance of Immunophenotypic Markers Expressed in Different Treatment Protocols of Pediatric Patients With T-ALL in Developing Countries. 61
28624542 2017
29
Severe Hyponatremia in a Single-Center Series of 84 Homogenously Treated Children With Acute Lymphoblastic Leukemia. 61
28060134 2017
30
The role of ZAP70 kinase in acute lymphoblastic leukemia infiltration into the central nervous system. 61
27686375 2017
31
[Clinical Characteristics and Prognosis of 21 Cases of Acute Lymphoblastic Leukemia with Central Nervous System Leukemia]. 61
28024476 2016
32
[Critical roles of matrix metalloproteinases secreted by leukemic cells in the pathogenesis of central nervous system leukemia]. 61
28088972 2016
33
[The prognostic significance of proportion of blasts in bone marrow on day 14 during induction chemotherapy in patients with adult Ph-negative acute lymphoblastic leukemia]. 61
27431075 2016
34
Transverse myelopathy occurring with intrathecal administration of methotrexate and cytarabine chemotherapy: A case report. 61
27313742 2016
35
Outcome of Children with Standard-Risk T-Lineage Acute Lymphoblastic Leukemia--Comparison among Different Treatment Strategies. 61
26485054 2016
36
Paving the road ahead for CD19 CAR T-cell therapy. 61
26335422 2015
37
[Leukotriene B4 level in cerebrospinal fluid of patients with tuberculosis meningitis and clinical significance]. 61
26271986 2015
38
Blastic plasmacytoid dendritic cell neoplasm with leukemic manifestation and ETV6 gene rearrangement: A case report. 61
25780395 2015
39
Comprehensive craniospinal radiation for controlling central nervous system leukemia. 61
25539370 2014
40
Advances in treatment of de-novo pediatric acute myeloid leukemia. 61
25226383 2014
41
Superior survival of unmanipulated haploidentical hematopoietic stem cell transplantation compared with chemotherapy alone used as post-remission therapy in adults with standard-risk acute lymphoblastic leukemia in first complete remission. 61
24747334 2014
42
Establishment of NOD/SCID mouse model of central nervous system leukemia. 61
24927394 2014
43
[Research progress on drug-loaded microbubble targeting treatment of central nervous system leukemia]. 61
24989314 2014
44
The emerging and diverse roles of sirtuins in cancer: a clinical perspective. 61
24133372 2013
45
[Analysis of multicenter efficacy of acute lymphoblastic leukemia in older children]. 61
23906450 2013
46
Outcome of childhood acute Lymphoblastic leukemia in Egyptian children: a challenge for limited health resource countries. 61
23394310 2013
47
A practical strategy of monitoring minimal residue disease and intervention for central nervous system relapse of childhood acute lymphoblastic leukemia: a single Chinese center's experience. 61
23787730 2013
48
The soluble VEGF receptor 1 and 2 expression in cerebral spinal fluid as an indicator for leukemia central nervous system metastasis. 61
23400753 2013
49
[Expression of osteopontin in central nervous system leukemia and its clinical significance]. 61
23628025 2013
50
Diagnosis and treatment of a patient with isolated spinal granulocytic sarcoma: A case report. 61
23599768 2013

Variations for Central Nervous System Leukemia

Expression for Central Nervous System Leukemia

Search GEO for disease gene expression data for Central Nervous System Leukemia.

Pathways for Central Nervous System Leukemia

Pathways related to Central Nervous System Leukemia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.56 CD34 CD33 CD19
2 11.42 MME CD34 CD33 CD19 ANPEP
3 11.2 MME CD34 CD19
4 11.1 MME CD7 CD34 CD33 CD19 ANPEP

GO Terms for Central Nervous System Leukemia

Cellular components related to Central Nervous System Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 8.92 CD34 CD33 CD19 ANPEP

Biological processes related to Central Nervous System Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of immune response GO:0050776 8.8 CD34 CD33 CD19

Molecular functions related to Central Nervous System Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor activity GO:0038023 8.8 CD7 CD33 ANPEP

Sources for Central Nervous System Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....